Hepatitis is a chronic disease which is caused due to viral infection in the liver. There are 5 types of hepatitis, namely, hepatitis A, B, C, D, and E. Hepatitis is the inflammation of the liver. This condition can be self-limiting or can progress to fibrosis, cirrhosis or liver cancer. Hepatitis viruses are the most common cause of hepatitis in the world. However, other infections, toxic substances, and autoimmune diseases can also cause hepatitis.
According to our report, “Global Hepatitis Drugs Market Outlook 2022”, the treatment of hepatitis C has been difficult. This is due to the low rate of treatment success and high rate of treatment discontinuation due to side effects. Current standard therapy for hepatitis C consists of pegylated interferon alpha and ribavirin. Both of these have non-specific and largely unknown mechanisms of action.
Owing to the technological advancements, new therapies are being developed for the treatment of hepatitis C. Direct acting anti-viral medication is one such medication which has revolutionized the hepatitis C treatment market. In 2011, the first generation of direct-acting antivirals, like Vertex’s Incivek and Merck’s Victrelis, were launched in the US market for genotype 1 patients. However, the approval of first NS5B inhibitor, Gilead’s Sovaldi, in 2013 was the main breakthrough in the hepatitis C treatment market. Moreover, the USFDA approved supplemental applications for Sovaldi and Harvoni to treat hepatitis C virus in children ages 12 to 17 in 2017.
The report segments the market on the basis of drug type, molecule type, and region. On the basis of drugs, the report provides current and forecasted market for drugs used in each type of hepatitis separately. Moreover, the report also segments the market according to molecules into small molecules (chemical drugs) and large molecules. The report also provides the regional analysis. The regions considered in the report include North America, Europe, Asia-Pacific, and Rest of the World. North America is the largest market for hepatitis drugs.
The next part of the report covers the pipeline analysis. The report also provides opportunity analysis which will help the client to understand the drug for each type of hepatitis with highest growth potential in each region. Moreover, it will also help the client to understand the highest growth potential region for each drug.
The later part of the report covers the competitive landscape and company profiles of major players operating in this market. The competitive landscape chapter provides insight regarding the market share of players operating in the market and the major strategies adopted by them for enhancing their market share. The company profile chapter includes the business overview, financials (Hepatitis drugs sales, if available; revenue of the segment in which hepatitis drugs fall) product portfolio & pipeline of hepatitis drugs, regions in which hepatitis drugs are marketed by the company and hepatitis drugs related developments. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.